Intravenous administration of anti-vascular endothelial growth factor humanized monoclonal antibody bevacizumab improves articular cartilage repair

Arthritis Research and Therapy

Volumn 12, Issue 5, 2010, Pages

  Nagai, Toshihiro ^a   Sato, Masato ^a   Kutsuna, Toshiharu ^a   Kokubo, Mami ^a   Ebihara, Goro ^a   Ohta, Naoshi ^a   Mochida, Joji ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CHONDROMODULIN; PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ARTICULAR CARTILAGE; BONE DEFECT; CARTILAGE CELL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; NONHUMAN; PATELLA; PHENOTYPE; POSTOPERATIVE PERIOD; PROTEIN EXPRESSION; RABBIT; ANIMAL; DRUG EFFECT; INJURY; INTRAVENOUS DRUG ADMINISTRATION; KNEE; METABOLISM; PATHOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; CARTILAGE, ARTICULAR; FEMALE; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAVENOUS; KNEE JOINT; RABBITS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77956933050     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3142     Document Type: Article

References (59)

1. Paget J. Healing of cartilage. Clin Orthop Relat Res 1969, 64:7-8.
2. Pridie KH. A method of resurfacing osteoarthritic knee joints. J Bone Joint Surg Br 1959, 41:618-619.
3. Muller B, Kohn D. Indication for and performance of articular cartilage drilling using the Pridie method. Orthopade 1999, 28:4-10.
4. Insall JN. Intra-articular surgery for degenerative arthritis of the knee. A report of the work of the late K. H. Pridie. J Bone Joint Surg Br 1967, 49:211-228.
5. Insall J. The Pridie debridement operation for osteoarthritis of the knee. Clin Orthop 1974, 101:61-67.
6. Steadman J, Rodkey W, Briggs K, Rodrigo J. The microfracture technique in the management of complete cartilage defects in the knee joint. Orthopade 1999, 28:26-32.
7. Steadman J, Rodkey W, Rodrigo J. Microfracture: surgical technique and rehabilitation to treat chondral defects. Clin Orthop Relat Res 2001, (391 Suppl):S362-S369.
8. Steadman J, Rodkey W, Briggs K. Microfracture to treat full-thickness chondral defects: surgical technique, rehabilitation, and outcomes. J Knee Surg 2002, 15:170-176.
9. Mithoefer K, Williams RJ, Warren RF, Potter HG, Spock CR, Jones EC, Wickiewicz TL, Marx RG. Chondral resurfacing of articular cartilage defects in the knee with the microfracture technique: surgical technique. J Bone Joint Surg Am 2006, 88:294-304. 10.2106/JBJS.F.00292, 16951101.
10. Hangody L, Kish G, Karpati Z, Udvarhelyi I, Szerb I, Bely M. Autogenous osteochondral graft technique for replacing knee cartilage defects in dogs. Orthopedics 1997, 5:175-181.
11. Hangody L, Feczko P, Bartha L, Bodo G, Kish G. Mosaicplasty for the treatment of articular defects of the knee and ankle. Clin Orthop Relat Res 2001, (391 Suppl):S328-S336.
12. Szerb I, Hangody L, Duska Z, Kaposi NP. Mosaicplasty: long-term follow-up. Bull Hosp Jt Dis 2005, 63:54-62.
13. Brittberg M, Lindahl A, Nilsson A, Ohlsson C, Isaksson O, Peterson L. Treatment of deep cartilage defects knee with autologus chondrocyte transplantation. N Engl J Med 1994, 331:889-895. 10.1056/NEJM199410063311401, 8078550.
14. Peterson L, Minas T, Brittberg M, Lindahl A. Treatment of osteochondritis dissecans of the knee with autologouschondrocyte transplantation: results at two to ten years. J Bone Joint Surg Am 2003, 85-A Suppl 2:17-24.
15. Zaslav K, Cole B, Brewster R, DeBerardino T, Farr J, Fowler P, Nissen C, . STAR Study Principal Investigators A prospective study of autologous chondrocyte implantation in patients with failed prior treatment for articular cartilage defects of the knee: results of the Study of the Treatment of Articular Repair (STAR) clinical trial. Am J Sports Med 2009, 37:42-55. 10.1177/0363546508322897, 18927254, STAR Study Principal Investigators.
16. Moseley JB, Anderson AF, Browne JE, Mandelbaum BR, Micheli LJ, Fu F, Erggelet C. Long-term durability of autologus chondrocyte implantation: a multicenter, observational study in US patients. Am J Sports Med 2010, 38:238-46. 10.1177/0363546509348000, 20448191.
17. Darling EM, Athanasiou KA. Articular cartilage bioreactor and bioprocess. Tissue Eng 2003, 9:9-26. 10.1089/107632703762687492, 12625950.
18. Backwalter JA, Lohmander S. Operative treatment of osteoarthrosis. Current practice and future development. J Bone Joint Surg Am 1994, 76:1405-1418.
19. Freed LE, Grande DA, Lingbin Z, Emmanual J, Marquis JC, Langer R. Joint resurfacing using allograft chondrocytes and synthetic biodegradable polymer scaffolds. J Biomed Mater Res 1994, 28:891-899. 10.1002/jbm.820280808, 7983087.
20. Hunziker EB. Articular cartilage repair: basic science and clinical progress. A review of the current status and prospects. Osteoarthritis Cartilage 2002, 10:432-463. 10.1053/joca.2002.0801, 12056848.
21. Marcacci M, Berruto M, Brocchetta D, Delcogliano A, Ghinelli D, Gobbi A, Kon E, Pederzini L, Rosa D, Sacchetti GL, Stefani G, Zanasi S. Articular cartilage engineeiring with Hyalograft C: 3-year clinical results. Clin Orthop Relat Res 2005, 435:96-105. 10.1097/01.blo.0000165737.87628.5b, 15930926.
22. Crawford DC, Heveran CM, Cannon WD, Foo LF, Potter HG. An autologus cartilage tissue implant NeoCart for treatment of grade III chondral injury to the distal femur: prospective clinical safety trial at 2 years. Am J Sports Med 2009, 37:1334-1343. 10.1177/0363546509333011, 19448048.
23. Nagai T, Sato M, Furukawa KS, Kutsuna T, Ohta N, Ushida T, Mochida J. Optimization of allograft implantation using scaffold-free chondrocyte plates. Tissue Eng Part A 2008, 14:1225-1235. 10.1089/ten.tea.2007.0225, 18489244.
24. Nagai T, Furukawa KS, Sato M, Ushida T, Mochida J. Characteristics of a scaffold-free articular chondrocyte plate grown in rotational culture. Tissue Eng Part A 2008, 14:1183-1193. 10.1089/ten.tea.2007.0114, 18433308.
25. Mainil-Varlet P, Rieser F, Grogan S, Mueller W, Saager C, Jakob RP. Articular cartilage repair using a tissue-engineered cartilage-like implant: an animal study. Osteoarthritis Cartilage 2001, 9 Suppl A:S6-S15. 10.1053/joca.2001.0438, 11680690.
26. Brehm W, Aklin B, Yamashita T, Rieser F, Trub T, Jakob RP, Mainil-Varlet P. Repair of superficial osteochondral defects with an autologous scaffold-free cartilage construct in a caprine model: implantation method and short-term results. Osteoarthritis Cartilage 2006, 14:1214-1226. 10.1016/j.joca.2006.05.002, 16820305.
27. Park K, Huang J, Azar F, Jin RL, Min BH, Han DK, Hasty K. Scaffold-free, engineered porcine cartilage construct for cartilage defect repair: in vitro and in vivo study. Artif Organs 2006, 30:586-596. 10.1111/j.1525-1594.2006.00267.x, 16911312.
28. Caplan AI, Elyaderani M, Mochizuki Y, Wakitani S, Goldberg VM. Principles of cartilage repair and regeneration. Clin Orthop Relat Res 1997, 342:254-272. 10.1097/00003086-199709000-00033, 9308548.
29. Nagai T, Sato M, Furukawa KS, Kutsuna T, Ohta N, Ushida T, Mochida J. Repair of total thickness defect of articular cartilage with scaffold-free chondrocyte plate. Proceedings of 55th Annual Meeting, Orthopaedic Research Society, 22-25 February 2009, Las Vegas, NV, USA.
30. Herbert H, Louis F, William N, Thomas C, John H, William H, Jordan B, Ari B, Susan G, Eric H, Napoleone F, Gwen F, Beth R, Robert R, Fairooz K. Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342. 10.1056/NEJMoa032691, 15175435.
31. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001, 7:987-989. 10.1038/nm0901-987, 11533692.
32. Willet CG, Boucher Y, Di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK. Direct evidence the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004, 10:145-147. 10.1038/nm988, 2693485, 14745444.
33. Hayami T, Funaki H, Yaoeda K, Mitui K, Yamagiwa H, Tokunaga K, Hatano H, Kondo J, Hiraki Y, Yamamoto T, Duong le T, Endo N. Expression of the cartilage derived anti-angiogenic factor chondromodulin-I decreases in the early stage of experimental osteoarthritis. J Rheumatol 2003, 30:2207-2217.
34. O'Driscoll SW, Keeley FW, Salter RB. Durability of regenerated articular cartilage produced by free autogenous periosteal grafts in major full-thickness defects in joint surfaces under the influence of continuous passive motion: a follow-up report at one year. J Bone Joint Surg Am 1998, 70:595-606.
35. Eskens FA. Angiogenesis inhibitors in clinical development. Br J Cancer 2004, 90:1-7. 10.1038/sj.bjc.6601401, 2395335, 14710197.
36. Branavan S, Lorraine EH, Ewa MP. Modulation angiogenesis. JAMA 2004, 292:972-977. 10.1001/jama.292.8.972, 15328330.
37. Solchaga LA, Yoo JU, Lundberg M, Dennis JE, Huibregtse BA, Goldberg VM, Caplan AI. Hyaluronan-based polymers in the treatment of osteochondral defects. J Orthop Res 2000, 18:773-780. 10.1002/jor.1100180515, 11117300.
38. Shapiro F, Koide S, Glimcher MJ. Cell origin and differentiation in the repair of full-thickness defects of articular cartilage. J Bone Joint Surg Am 1993, 75:532-553.
39. Kubo S, Cooper GM, Matsumoto T, Phillippi JA, Corsi KA, Usas A, Li G, Fu FH, Huard J. Blocking vascular endothelial growth factor with soluble Flt-1 improves the chondrogenic potential of mouse skeletal muscle-derived stem cells. Arthritis Rheum 2009, 60:155-165. 10.1002/art.24153, 19116905.
40. Hashimoto S, Ochs RL, Komiya S, Lotz M. Linkage of chondrocyte apoptosis and cartilage degradation in human osteoarthritis. Arthritis Rheum 1998, 41:1632-1638. 10.1002/1529-0131(199809)41:9<1632::AID-ART14>3.0.CO;2-A, 9751096.
41. Hashimoto S, Creighton-Achermann L, Takahashi K, Amiel D, Coutts RD, Lotz M. Development and regulation of osteophyte formation during experimental osteoarthritis. Osteoarthritis Cartilage 2002, 10:180-187. 10.1053/joca.2001.0505, 11869078.
42. Enomoto H, Inoki I, Komiya K, Shiomi T, Ikeda E, Obata K, Matsumoto H, Toyama Y, Okada Y. Vascular endothelial growth factor isoforms and their receptors are expressed in human osteoarthritic cartilage. Am J Pathol 2003, 162:171-181. 1851114, 12507900.
43. Tanaka E, Aoyama J, Miyauchi M, Takata T, Hanaoka K, Iwabe T, Tanne K. Vascular endothelial growth factor plays an important autocrine/paracrine role in the progression of osteoarthritis. Histochem Cell Biol 2005, 123:275-281. 10.1007/s00418-005-0773-6, 15856277.
44. Pufe T, Petersen W, Tillmann B, Mentlein R. The splice variants VEGF121 and VEGF189 of the angiogenic peptide vascular endothelial growth factor are expressed in osteoarthritic cartilage. Arthritis Rheum 2001, 44:1082-1088. 10.1002/1529-0131(200105)44:5<1082::AID-ANR188>3.0.CO;2-X, 11352239.
45. Pufe T, Harde V, Petersen W, Goldring MB, Tillmann B, Mentlein R. Vascular endothelial growth factor (VEGF) induces matrix metalloproteinase expression in immortalized chondrocytes. J Pathol 2004, 202:367-374. 10.1002/path.1527, 14991903.
46. Pufe T, Lemke A, Kurz B, Petersen W, Tillmann B, Grodzinsky AJ, Mentlein R. Mechanical overload induces VEGF in cartilage discs via hypoxia-inducible factor. Am J Pathol 2004, 164:185-192. 1602231, 14695332.
47. Murakami M, Iwai S, Hiratsuka S, Yamauchi M, Nakamura K, Iwakura Y, Shibuya M. Signaling of vascular endothelial growth factor receptor-1 tyrosine kinase promotes rheumatoid arthritis through activation of monocytes/macrophages. Blood 2006, 108:1849-1856. 10.1182/blood-2006-04-016030, 16709927.
48. Afuwape AO, Kiriakidis S, Paleolog EM. The role of the angiogenic molecule VEGF in the pathogenesis of rheumatoid arthritis. Histol Histopathol 2002, 17:961-972.
49. Gerber HP, Vu TH, Ryan AM, Kowalski J, Werb Z, Ferrara N. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med 1999, 5:623-628. 10.1038/9467, 10371499.
50. Carlevaro MF, Cermelli S, Cancedda R, Descalzi Cancedda F. Vascular endothelial growth factor (VEGF) in cartilage neovascularization and chondrocyte differentiation: auto-paracrine role during endochondral bone formation. J Cell Sci 2000, 113:59-69.
51. Yin M, Pacifici M. Vascular regression is required for mesenchymal condensation and chondrogenesis in the developing limb. Dev Dyn 2001, 222:522-533. 10.1002/dvdy.1212, 11747085.
52. Hiraki Y, Inoue H, Iyama K, Kamizono A, Ochiai M, Shukunami C, Iijima S, Suzuki F, Kondo J. Identification of chondromodulin I as a novel endothelial cell inhibitor: purification and its localization in the avascular zone of epiphyseal cartilage. J Biol Chem 1997, 272:32419-32426. 10.1074/jbc.272.51.32419, 9405451.
53. Kitahara H, Hayami T, Tokunaga K, Endo N, Funaki H, Yoshida Y, Yaoita E, Yamamoto T. Chondromodulin-I expression in rat articular cartilage. Arch Histol Cytol 2003, 66:221-228. 10.1679/aohc.66.221, 14527163.
54. Gonzalez AM, Buscaglia M, Ong M, Baird A. Distribution of basic fibroblast growth factor in the 18-day rat fetus: localization in the basement membranes of diverse tissues. J Cell Biol 1990, 110:753-765. 10.1083/jcb.110.3.753, 2116039, 1689733.
55. Gelb DE, Rosier RN, Puzas JE. The production of transforming growth factor-beta by chick growth plate chondrocytes in short term monolayer culture. Endocrinology 1990, 127:1941-1947. 10.1210/endo-127-4-1941, 2401238.
56. Thiennu HV, Shipley JM, Bergers G, Burger JE, Helms JA, Hanahan D, Shapiro SD, Senior RM, Werb Z. MMP-9/Gelatinase B is a key regulator of growth plate angiogenesis and apoptosis. Cell 1998, 93:411-422. 10.1016/S0092-8674(00)81169-1, 2839071, 9590175.
57. Zelzer E, Mamluk R, Ferrara N, Johnson RS, Schipani E, Olsen BR. VEGFA is necessary for chondrocyte survival during bone development. Development 2004, 131:2161-2171. 10.1242/dev.01053, 15073147.
58. Haigh JJ, Gerber HP, Ferrara N, Wagner EF. Conditional inactivation of VEGF-A in areas of collagen2a1 expression results in embryonic lethality in the heterozygous state. Development 2000, 127:1445-1453.
59. Van der Flier M, Coenjaerts FE, Mwinzi PN, Rijkers E, Ruyken M, Scharringa J, Kimpen JLL, Hoepelman AIM, Geelen SPM. Antibody neutralization of vascular endothelial growth factor (VEGF) fails to attenuate vascular permeability and brain edema in experimental pneumococcal meningitis. J Neuroimmunol 2005, 160:170-177. 10.1016/j.jneuroim.2004.11.013, 15710470.